pravastatin sodium
Phase 3Small molecule
Tevapravastatin sodium is one of 148 small molecule programs targeting Liver Cancer. It is currently in Phase 3.
4
Indications
16
Total Trials
0
Active Trials
147
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Intron a
SanofiPhase 3
Tibsovo
SServier
Phase 3
pravastatin sodium
TevaPhase 3
ALL-Trans Retinoid Acid
UUniversity of Ulm
Phase 3
Capoten
GSKPhase 3
PR1 Leukemia Peptide Vaccine
TThe Vaccine Company
Phase 3
Iomab-B
AActinium Pharmaceuticals
Phase 3
Leukine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fasting Conditions3 trials
Acute Myeloid Leukemia2 trials
Statin2 trials
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions
Completed·—·Phase 1·NCT01146093·24 enrolled
Myelodysplastic Syndromes1 trial
Effectiveness1 trial
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006412·630 enrolled
7 more indications
Small Cell Lung Cancer1 trial
Drug1 trial
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00017758·56 enrolled
Interaction1 trial
Endothelial Function1 trial
Liver Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pravastatin sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]